News of the company


On October 29, 2021, a master class "Simple and complex diagnosis" was held online within the All-Ukrainian Professional Respiratory School.

The event was attended by more than 1,400 health professionals from all over Ukraine. The master class addressed topical issues of diagnosis and treatment of upper respiratory tract diseases, community-acquired pneumonia, chronic obstructive pulmonary disease and bronchial asthma.

Bil Bohdan Nazarovych, Candidate of Medical Sciences, Head of the Kyiv City Research and Practice Center for Endoscopic Rhinolaryngology, Honored Doctor of Ukraine was a leading speaker of the master class. He presented his report "Experience of antihistamines in the practice of otolaryngologist"to the participants.

In his report, the speaker noted that according to research conducted by scientists around the world, the number of patients with allergic rhinitis exceeds 500 million.

Symptoms of allergic rhinitis affect the daily activities of patients, sleep and their quality of life.

First-generation antihistamines have a negative effect on the cognitive functions of patients, such as memory, attention, thinking, sleep and daily activity. They impair the performance and success of children in school.

Ananta Medicare presents a third-generation antihistamine on the Ukrainian market – Tigofast (fexofenadine) meets all the requirements of EAACI * and ARIA ** and it is a perfect antihistamine agent.

Numerous studies have shown that Tigofast has the least effect on the psychomotor function of patients. This allows to use this drug for the treatment of allergic rhinitis in a wide range of patients, including drivers, pilots and people engaged in mental activity.

Tigofast quickly eliminates all the symptoms of allergic rhinitis due to the high occupation of H-histamine receptors. In addition, Tigofast has a minimal risk of drug interactions, so it can be used for the elderly and patients with associated renal and hepatic pathology, without the need to reduce the dosage.

Tigofast is recommended for the symptomatic treatment of seasonal allergic rhinitis (Tigofast-120) and the symptomatic treatment of chronic idiopathic urticaria (Tigofast-180) in adults and children over 12 years of age, 1 tablet once a day.

Tigofast is your allergy protector!

You can read more about Tigofast in the instructions for medical use.

Registration certificate No. UA/2730/01/02


"All-Ukrainian Professional Respiratory School" opens its doors to those health professionals who seek to improve their professional level.

We invite you to listen to the report of Bil Bohdan Nazarovych at the following link (report start time 1:14 min).


*EAACI - European Academy of Allergy and Clinical Immunology

**Allergic Rhinitis and its Impact on Asthma